EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L12	21	LEVENTER adj STEVEn	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 17:35
L13	51	HARRIS adj HERBERT	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 17:35
L14	41	KUCHARIK adj 'ROBERT	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 17:36
L15	41	KUCHARIK adj ROBERT	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 17:36
L16	76	l12 l13 l14	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 17:36
L18	21	l16 and 2,3-benzodiazepines	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 17:40
L19	6125	xia.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 17:40
L20	1	l19 and 2,3-benzodiazepines	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 17:45

EAST Search History

L21	2	"5492907".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 17:45
L22	28	l16 and benzodiazepine	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 18:47
L23	0	tofosipam	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 18:48
L24	178	tofisopam	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 18:48
L25	13	l24 same metabolite$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/12/12 18:48
L26	16	("3736315" | "4322346" | "4423044" | "4614740" | "4835152" | "4840948" | "5204343" | "5288863" | "5459137" | "5519019" | "5521174" | "5639751" | "5891871" | "6075018" | "6080736").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/12/12 20:01
L27	9175	l26 and 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3 -benzodiazepine	US-PGPUB; USPAT; USOCR	OR	OFF	2007/12/12 19:54
L28	770	l26 and 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine	US-PGPUB; USPAT; USOCR	OR	OFF	2007/12/12 19:54
L29	2	l26 and dimethoxy-5H-2,3-benzodiazepine	US-PGPUB; USPAT; USOCR	OR	OFF	2007/12/12 19:57
L30	2	l26 and hydroxy and methoxyphenyl	US-PGPUB; USPAT; USOCR	OR	OFF	2007/12/12 19:57
L31	12	l26 and compound.clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/12/12 20:01
L32	5	l26 and compounds.clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/12/12 20:01
L33	13	l26 and formula.clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/12/12 20:01

EAST Search History

L34	0	l26 and formulae.clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/12/12 20:01
L35	13	l31 l32 l33	US-PGPUB; USPAT; USOCR	OR	OFF	2007/12/12 20:02

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALXS1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* *
STN maintenance downtime to be extended

The normal maintenance downtime for STN will be extended on December 15. STN will be unavailable beginning Saturday, December 15, at 17:00 U.S. Eastern Standard Time until Sunday, December 16, at 01:00.

The normal schedule for STN maintenance downtime (22:00 to 01:00) will resume on December 22.

* *

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:14:41 ON 12 DEC 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:14:58 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0
DICTIONARY FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s 730962-81-9
L1 1 730962-81-9
(730962-81-9/RN)

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 730962-81-9 REGISTRY
ED Entered STN: 23 Aug 2004
CN Phenol, 5-[(5S)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl]-2-methoxy- (CA INDEX NAME)
OTHER NAMES:
CN (S)-1-(3-Hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine
FS STEREOSEARCH
MF C21 H24 N2 O4

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 730962-81-9/cn
L2 0 730962-81-9/CN

=> s 730962-81-9/rn
L3 1 730962-81-9/RN

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 730962-81-9 REGISTRY
ED Entered STN: 23 Aug 2004
CN Phenol, 5-[(5S)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl]-2-methoxy- (CA INDEX NAME)
OTHER NAMES:
CN (S)-1-(3-Hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine
FS STEREOSEARCH
MF C21 H24 N2 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.30	9.51

FILE 'CAPLUS' ENTERED AT 17:15:39 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Dec 2007 VOL 147 ISS 25
FILE LAST UPDATED: 11 Dec 2007 (20071211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d l4 bib ab 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1080692 CAPLUS
DN 142:56375
TI Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines
IN Leventer, Steven M.; Harris, Herbert W.; Kucharik, Robert F.
PA USA
SO U.S. Pat. Appl. Publ., 33 pp.

CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004254173	A1	20041216	US 2003-461290	20030613
PRAI	US 2003-461290		20030613		

OS MARPAT 142:56375

AB There is provided a method of modulating dopamine responses in the central nervous system of an individual or a method of treating a dopamine-mediated disorder in an individual not suffering from seizures or convulsions which comprises administering to the individual an effective amount of at least one compound of formula (I) [R1 = C1-7 hydrocarbyl or C2-6 heteroalkyl; R2 = H, C1-7 hydrocarbyl; wherein R1 and R2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring; R3, R4, R5, R6 = OH, C1-7 hydrocarbyl, CF3, C1-7 hydrocarbyloxy, acyloxy, NH2, -NH(C1-6alkyl), -N(C1-6 alkyl)2, -NH-acyl, halogen; wherein R5 and R6 may combine to form a 5-, 6- or 7-membered heterocyclic ring] or pharmaceutically acceptable salts thereof or said compound comprising an (S)-enantiomer substantially free of the (R)-enantiomer of the same compound The above dopamine-mediated disorder comprises a neurol. disorder or a neuropsychiatric disorder. The neurol. disorder includes Huntington's chorea, Parkinson's disease, periodic limb movement syndrome, restless leg syndrome, hyperkinesias, Tourette's syndrome, Pick's disease, punch drunk syndrome, progressive subnuclear palsy, multiple systems atrophy, Landau-Kleffner syndrome, benign essential blepharospasm, amyotrophic lateral sclerosis, medication-induced movement disorders, and cognitive disorders. The neuropsychiatric disorder includes psychosis, personality disorders, psychiatric mood disorders, conduct and impulse disorders, schizophrenia, bipolar disorders, dysphoric mania, anxiety disorders, depression, panic disorders, agoraphobia, obsessive-compulsive disorders and eating disorders. Thus, 4.41 g (10 mmol) 1-(3,4-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxyisobenzopyrilium chloride hydrochloride was dissolved in methanol (35 mL) at a temperature of 40°. After cooling to 20-25°, hydrazine hydrate (0.75 g, 15 mmol, dissolved in 5 mL methanol) was added and the resulting mixture was allowed to react while monitoring the reaction by HPLC and when complete, was evaporated to dryness. The residue was triturated with cold water (3 mL), filtered and dried to yield the crude 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-hydroxy-8-methoxy-5H-2,3-benzodiazepine (racemic tofisopam) which was subsequently triturated with hot EtOAc to yield the pure product. Racemic tofisopam was resolved by a Chirobiotic V column (ASTEAC, Whippany, N.J.) to give (R)-tofisopam and (S)-tofisopam. (R)-tofisopam did not affect apomorphine-induced hypothermia in mice. Racemic tofisopam at 64 mg/kg tended to behave as a weak dopamine antagonist, i.e., lowering the rectal temperature at the thirty and sixty minute time points. However this trend was not statistically significant. (S)-tofisopam behaved as a weak dopamine antagonist at the 16 mg/kg dose at sixty minutes after apomorphine administration, i.e., showing a slight but statistically significant elevation in temperature At the higher doses, (S)-tofisopam demonstrated dopamine antagonism at both the thirty minute and sixty minute time points, i.e., lowering the rectal temperature at both time points.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:995773 CAPLUS
DN 141:410971
TI A preparation of 2,3-benzodiazepine derivatives, useful as antipyretic agents
IN Harris, Herbert W.; Kucharik, Robert F.
PA Vela Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 369,823.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004229866	A1	20041118	US 2004-781422	20040217
	US 2004162284	A1	20040819	US 2003-369823	20030219
	US 2004224943	A1	20041111	US 2004-827839	20040419
PRAI	US 2003-369823	A2	20030219		
	US 2004-781422	A2	20040217		

OS MARPAT 141:410971

AB The invention relates to a preparation of 2,3-benzodiazepine derivs. of formula I [wherein: R1 is hydrocarbyl or heteroalkyl; R2 is H or hydrocarbyl; R1 and R2 may combine to form a (carbo/hetero)cyclic ring; R3 and R4 are independently selected from OH, SH, NO2, halogen, or S-alkyl, etc.; R5 is substituted phenyl], useful as antipyretic agents. For instance, (S)-2,3-benzodiazepine derivative II was prepared via heterocyclization of diketone III with hydrazine and subsequent resolution The prepared title compds. were tested in stress-induced hypothermia assay. (S)-enantiomer of tofisopam showed higher activity than the racemate or the (R)-enantiomer [dose: 64 mg/kg, (S)-tofisopam: 33 °C, (R)-tofisopam: 35.25 °C, racemate: 33.75 °C].

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:633284 CAPLUS

DN 141:162379

TI Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof

IN Harris, Herbert W.; Leventer, Steven M.; Kucharik, Robert F.

PA Vela Pharmaceuticals, Inc., USA

SO U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004152695	A1	20040805	US 2003-728179	20031203
	CA 2510275	A1	20040819	CA 2003-2510275	20031203
	WO 2004069155	A2	20040819	WO 2003-US38641	20031203
	WO 2004069155	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003303312	A1	20040830	AU 2003-303312	20031203
	EP 1575521	A2	20050921	EP 2003-815301	20031203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514084	T	20060427	JP 2004-568017	20031203
	MX 2005PA05893	A	20060208	MX 2005-PA5893	20050602
PRAI	US 2002-430770P	P	20021203		
	WO 2003-US38641	W	20031203		

AB Pharmaceutical compns. comprise 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or a pharmaceutically acceptable salt thereof. The compns. are used for treating, preventing or delaying the onset of disorders mediated by LTB4 or TXA2.

=> file medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.90	19.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

FILE 'ADISCTI' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 17:17:33 ON 12 DEC 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CAPLUS' ENTERED AT 17:17:33 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DDFB' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 17:17:33 ON 12 DEC 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 17:17:33 ON 12 DEC 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 IMSWORLD Publications Ltd

FILE 'IPA' ENTERED AT 17:17:33 ON 12 DEC 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'KOSMET' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'MEDLINE' ENTERED AT 17:17:33 ON 12 DEC 2007

FILE 'NAPRALERT' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 Gale Group. All rights reserved.

FILE 'NUTRACEUT' ENTERED AT 17:17:33 ON 12 DEC 2007
Copyright 2007 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PASCAL' ENTERED AT 17:17:33 ON 12 DEC 2007
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 WIPO

FILE 'PHARMAML' ENTERED AT 17:17:33 ON 12 DEC 2007
Copyright 2007 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 Informa UK Ltd.

FILE 'PHIN' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 Informa UK Ltd.

FILE 'SCISEARCH' ENTERED AT 17:17:33 ON 12 DEC 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'TOXCENTER' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USGENE' ENTERED AT 17:17:33 ON 12 DEC 2007
COPYRIGHT (C) 2007 SEQUENCEBASE CORP

FILE 'USPATFULL' ENTERED AT 17:17:33 ON 12 DEC 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:17:33 ON 12 DEC 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:17:33 ON 12 DEC 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l3
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE

'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L5 7 L3

=> s l5 bib abs 1-7
MISSING OPERATOR L5 BIB
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l5 bib ab 1-7
MISSING OPERATOR L5 BIB
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l5 bib ab 1-7
MISSING OPERATOR L5 BIB
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l5 bib ab 1-7

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1080692 CAPLUS
DN 142:56375
TI Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines
IN Leventer, Steven M.; Harris, Herbert W.; Kucharik, Robert F.
PA USA
SO U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004254173	A1	20041216	US 2003-461290	20030613
PRAI	US 2003-461290		20030613		

OS MARPAT 142:56375
AB There is provided a method of modulating dopamine responses in the central nervous system of an individual or a method of treating a dopamine-mediated disorder in an individual not suffering from seizures or convulsions which comprises administering to the individual an effective amount of at least one compound of formula (I) [R1 = C1-7 hydrocarbyl or C2-6 heteroalkyl; R2 = H, C1-7 hydrocarbyl; wherein R1 and R2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring; R3, R4, R5, R6 = OH, C1-7 hydrocarbyl, CF3, C1-7 hydrocarbyloxy, acyloxy, NH2, -NH(C1-6alkyl), -N(C1-6 alkyl)2, -NH-acyl, halogen; wherein R5 and R6 may combine to form a 5-, 6- or 7-membered heterocyclic ring] or pharmaceutically acceptable salts thereof or said compound comprising an (S)-enantiomer substantially free of the (R)-enantiomer of the same compound The above dopamine-mediated disorder comprises a neurol. disorder or a neuropsychiatric disorder. The neurol. disorder includes Huntington's chorea, Parkinson's disease, periodic limb movement syndrome, restless leg syndrome, hyperkinesias, Tourette's syndrome, Pick's disease, punch drunk syndrome, progressive subnuclear palsy, multiple systems atrophy, Landau-Kleffner syndrome, benign essential blepharospasm, amyotrophic

lateral sclerosis, medication-induced movement disorders, and cognitive disorders. The neuropsychiatric disorder includes psychosis, personality disorders, psychiatric mood disorders, conduct and impulse disorders, schizophrenia, bipolar disorders, dysphoric mania, anxiety disorders, depression, panic disorders, agoraphobia, obsessive-compulsive disorders and eating disorders. Thus, 4.41 g (10 mmol) 1-(3,4-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxyisobenzopyrilium chloride hydrochloride was dissolved in methanol (35 mL) at a temperature of 40°. After cooling to 20-25°, hydrazine hydrate (0.75 g, 15 mmol, dissolved in 5 mL methanol) was added and the resulting mixture was allowed to react while monitoring the reaction by HPLC and when complete, was evaporated to dryness. The residue was triturated with cold water (3 mL), filtered and dried to yield the crude 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-hydroxy-8-methoxy-5H-2,3-benzodiazepine (racemic tofisopam) which was subsequently triturated with hot EtOAc to yield the pure product. Racemic tofisopam was resolved by a Chirobiotic V column (ASTEAC, Whippany, N.J.) to give (R)-tofisopam and (S)-tofisopam. (R)-tofisopam did not affect apomorphine-induced hypothermia in mice. Racemic tofisopam at 64 mg/kg tended to behave as a weak dopamine antagonist, i.e., lowering the rectal temperature at the thirty and sixty minute time points. However this trend was not statistically significant. (S)-tofisopam behaved as a weak dopamine antagonist at the 16 mg/kg dose at sixty minutes after apomorphine administration, i.e., showing a slight but statistically significant elevation in temperature At the higher doses, (S)-tofisopam demonstrated dopamine antagonism at both the thirty minute and sixty minute time points, i.e., lowering the rectal temperature at both time points.

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:995773 CAPLUS
DN 141:410971
TI A preparation of 2,3-benzodiazepine derivatives, useful as antipyretic agents
IN Harris, Herbert W.; Kucharik, Robert F.
PA Vela Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 369,823.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004229866	A1	20041118	US 2004-781422	20040217
	US 2004162284	A1	20040819	US 2003-369823	20030219
	US 2004224943	A1	20041111	US 2004-827839	20040419
PRAI	US 2003-369823	A2	20030219		
	US 2004-781422	A2	20040217		

OS MARPAT 141:410971
AB The invention relates to a preparation of 2,3-benzodiazepine derivs. of formula I [wherein: R1 is hydrocarbyl or heteroalkyl; R2 is H or hydrocarbyl; R1 and R2 may combine to form a (carbo/hetero)cyclic ring; R3 and R4 are independently selected from OH, SH, NO2, halogen, or S-alkyl, etc.; R5 is substituted phenyl], useful as antipyretic agents. For instance, (S)-2,3-benzodiazepine derivative II was prepared via heterocyclization of diketone III with hydrazine and subsequent resolution The prepared title compds. were tested in stress-induced hypothermia assay. (S)-enantiomer of tofisopam showed higher activity than the racemate or the (R)-enantiomer [dose: 64 mg/kg, (S)-tofisopam: 33 °C, (R)-tofisopam: 35.25 °C, racemate: 33.75 °C].

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:633284 CAPLUS
DN 141:162379
TI Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof
IN Harris, Herbert W.; Leventer, Steven M.; Kucharik, Robert F.

PA Vela Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004152695	A1	20040805	US 2003-728179	20031203
	CA 2510275	A1	20040819	CA 2003-2510275	20031203
	WO 2004069155	A2	20040819	WO 2003-US38641	20031203
	WO 2004069155	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003303312	A1	20040830	AU 2003-303312	20031203
	EP 1575521	A2	20050921	EP 2003-815301	20031203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514084	T	20060427	JP 2004-568017	20031203
	MX 2005PA05893	A	20060208	MX 2005-PA5893	20050602
PRAI	US 2002-430770P	P	20021203		
	WO 2003-US38641	W	20031203		

AB Pharmaceutical compns. comprise 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or a pharmaceutically acceptable salt thereof. The compns. are used for treating, preventing or delaying the onset of disorders mediated by LTB4 or TXA2.

L5 ANSWER 4 OF 7 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2004:187210 TOXCENTER
CP Copyright 2007 ACS
DN CA14110162379N
TI Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof
AU Harris, Herbert W.; Leventer, Steven M.; Kucharik, Robert F.
CS ASSIGNEE: Vela Pharmaceuticals, Inc.
PI US 2004152695 A1 5 Aug 2004
SO (2004) U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO.
CY UNITED STATES
DT Patent
FS CAPLUS
OS CAPLUS 2004:633284
LA English
ED Entered STN: 24 Aug 2004
Last Updated on STN: 23 Jan 2007
AB Pharmaceutical compns. comprise 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or a pharmaceutically acceptable salt thereof. The compns. are used for treating, preventing or delaying the onset of disorders mediated by LTB4 or TXA2.

L5 ANSWER 5 OF 7 USPATFULL on STN
AN 2004:321518 USPATFULL
TI Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines
IN Leventer, Steven M., Langhorne, PA, UNITED STATES
Harris, Herbert W., Merion, PA, UNITED STATES
Kucharik, Robert F., Glenmoore, PA, UNITED STATES

PI US 2004254173 A1 20041216
AI US 2003-461290 A1 20030613 (10)
DT Utility
FS APPLICATION
LREP DRINKER BIDDLE & REATH, ONE LOGAN SQUARE, 18TH AND CHERRY STREETS, PHILADELPHIA, PA, 19103-6996
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 1608
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds according to formula I: ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined herein, and wherein the compound comprises the (S)-enantiomer, administered for modulation of dopamine responses and treatment of dopamine-mediated disorders.

L5 ANSWER 6 OF 7 USPATFULL on STN
AN 2004:292777 USPATFULL
TI Method of lowering body temperature with (S)-2,3-benzodiazepines
IN Harris, Herbert W., Merion, PA, UNITED STATES
Kucharik, Robert F., Glenmoore, PA, UNITED STATES
PA Vela Pharmaceuticals, Inc., Lawrenceville, NJ (U.S. corporation)
PI US 2004229866 A1 20041118
AI US 2004-781422 A1 20040217 (10)
RLI Continuation-in-part of Ser. No. US 2003-369823, filed on 19 Feb 2003, PENDING
DT Utility
FS APPLICATION
LREP DRINKER BIDDLE & REATH, ONE LOGAN SQUARE, 18TH AND CHERRY STREETS, PHILADELPHIA, PA, 19103-6996
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1692
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ##STR1##

An (S)-2,3-benzodiazepine of Formula I, substantially isolated from the corresponding (R)-enantiomer thereof, is administered to lower the body temperature of an individual.

L5 ANSWER 7 OF 7 USPATFULL on STN
AN 2004:197389 USPATFULL
TI Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof
IN Harris, Herbert W., Merion, PA, UNITED STATES
Leventer, Steven M., Langhorne, PA, UNITED STATES
Kucharik, Robert F., Glenmoore, PA, UNITED STATES
PA Vela Pharmaceuticals, Inc., Lawrenceville, NJ (U.S. corporation)
PI US 2004152695 A1 20040805
AI US 2003-728179 A1 20031203 (10)
PRAI US 2002-430770P 20021203 (60)
DT Utility
FS APPLICATION
LREP DRINKER BIDDLE & REATH, ONE LOGAN SQUARE, 18TH AND CHERRY STREETS, PHILADELPHIA, PA, 19103-6996
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions comprise 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or a

pharmaceutically acceptable salt thereof. The compositions are used for treating, preventing or delaying the onset of disorders mediated by LTB.sub.4 or TXA.sub.2.

=> file ca

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.92	89.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-4.68

FILE 'CA' ENTERED AT 17:20:23 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Dec 2007 VOL 147 ISS 25
FILE LAST UPDATED: 6 Dec 2007 (20071206/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L6 3 L3

=> s l6 not l4
3 L3
L7 0 L6 NOT L4

=> file end
SESSION CONTINUES IN FILE 'CA'

=> file quit
'QUIT' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'CA'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 17:21:27 ON 12 DEC 2007

Google Scholar BETA

Web Images Video News Maps more »

tofisopam precursor - 2002 Search Ad Sc Sc

Scholar

Results 1 - 9 of 9 for **tofisopam precursor**. (0.06 seconds)

All Results
M Rizzo
E Ebbers
G Ariaans
J Houbiers
A Bruggink

Chromatographic separation of 2, 3-benzodiazepines - all 5 versions »
M Rizzo - Journal of Chromatography B: Biomedical Sciences and ..., 2000 - Elsevier
... a **precursor** of the pharmacologically active compound. The metabolic pathway of 2,3-BZs has been extensively studied in different species. **Tofisopam** metabolites ...
Cited by 11 - Related Articles - Web Search

Recent Advances in the Clinical Pharmacology of Benzodiazepines Part I: Pharmacokinetics
BS MD, GPMDS Psychiatrist - HUMAN PSYCHOPHARMACOLOGY, 1987 - doi.wiley.com
... At the other extreme is another desmethyldiazepam **precursor**, prazepam. It is slowly transformed into the active substance ... Triazolam Brotizolam **Tofisopam** ...
Related Articles - Web Search

Synthesis and structure-activity relationships of 2, 3-benzodiazepines as AMPA receptor antagonists. - all 2 versions »
M Zappalà, S Grasso, N Micale, S Polimeni, C De ... - Mini Rev Med Chem, 2001 - ingentaconnect.com
... 1, GYKI 52466 2, **Tofisopam** ... The required chiral **precursor** 25 was obtained with the highly effective biocatalytic reduction of 3-(3,4- methylene-dioxyphenyl ...
Related Articles - Web Search

[PDF] BEHANDLUNG VON DYSKINESIE MIT 2, 3-BENZODIAZEPINEN TRAITEMENT DE LA DYSKINÉSIE AVEC DES 2, 3- ...
A CZ, FR DE DK EE ES FI, GB GR, B JM... - NEUROSCIENCE, 2002 - publications.european-patent-office.org
... 10, 2002, pages 913-939, XP008026188 ISSN: 1381-6128 • BROTCHIE JM ET AL: "THE EFFECTS
OF **TOFISOPAM** ON THE ACTIONS INDUCED BY L - DOPA ADMINISTRATION IN THE ...
View as HTML - Web Search

Controlled racemization of optically active organic compounds: Prospects for asymmetric ... - all 6 versions »
EJ Ebbers, GJA Ariaans, JPM Houbiers, A Bruggink, ... - Tetrahedron, 1997 - Elsevier
Page 1. Pergamon PII: S0040-4020(97)00324-4 Tetrahedron, Vol. 53, No. 28, pp. 9417-9476, 1997 © 1997 Elsevier Science Ltd All rights reserved. ...
Cited by 71 - Related Articles - Web Search

Targeted ultrasound contrast agents
US Patent 6,264,917, 2001 - freepatentsonline.com
Patent Number: Advanced Search. Site Contents. Search Patents Use our search engine to find what you need. Data and Analytical Services Complete custom solutions ...
Cited by 1 - Related Articles - Cached - Web Search

Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US Patent 6,261,537, 2001 - freepatentsonline.com
Patent Number: Advanced Search. Site Contents. Search Patents Use our search engine

to find what you need. Data and Analytical Services Complete custom solutions ...
Cited by 4 - Related Articles - Cached - Web Search

[CITATION] The Impact of Alcoholism on the Family
P Symptomatology - Journal of Studies on Alcohol, 1975 - [New Brunswick, NJ, Journal of Studies on Alcohol
Related Articles - Web Search

[CITATION] Role and Outcome on Alcoholics'
A Processes - Journal of Studies on Alcohol, 1975 - [New Brunswick, NJ, Journal of Studies on Alcohol
Related Articles - Web Search

tofisopam precursor Search

Google Home - About Google - About Google Scholar

Google Scholar BETA

Web Images Video News Maps more »

tofisopam metabolite - 2002 Search

Ad Sc Sc

Scholar **All articles** - **Recent articles** Results **1** - **10** of about **22** for **tofisopam metabolite**. (**0.06** sec

All Results
M Rizzo
C Banki
B Testa
Y Gaillard
A Bond

Chromatographic separation of 2, 3-benzodiazepines - all 5 versions »
M Rizzo - Journal of Chromatography B: Biomedical Sciences and ..., 2000 - Elsevier
... 38]. The use of dimethyl silicone stationary phase gave better separation of **Tofisopam metabolites** than the cyanoethyl phase [48]. ...
Cited by 11 - Related Articles - Web Search

... for treating and preventing anxiety and anxiety disorders using optically pure (R) **tofisopam** - all 3 versions »
DW Landry, DF Klein... - US Patent 6,080,736, 2000 - Google Patents
... binding of BDZs is not due simply to pharmacokinetic factors since brain levels of diazepam and its **metabolite** desmethyldiazepam were unmodified by **tofisopam**. ...
Cited by 5 - Related Articles - Web Search

Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence - all 3 versions »
CM Banki - Journal of Neural Transmission, 1981 - Springer
... 91 conditions known to alter **metabolite** levels from sources other than central amine ... patients in the first days of abstinence received only **tofisopam**--a minor ...
Cited by 51 - Related Articles - Web Search

A comparison of the psychotropic profiles of **tofisopam** and diazepam
A Bond, M Lader - European Journal of Clinical Pharmacology, 1982 - Springer
... is slowly absorbed and distributed to the brain or it is a pro-drug and is transformed to an active **metabolite**. In vitro studies showed that **tofisopam** did not ...
Cited by 9 - Related Articles - Web Search

The so-called"interconversion" of stereoisomeric drugs: An attempt at clarification - all 3 versions »
B Testa, PA Carrupt, J Gal - Chirality, 1993 - doi.wiley.com
... **Tofisopam** thus offers an interesting and pharmacologically relevant example of ... stereose-
lectivity while the hydrogenation of the ketone **metabolite** is product ...
Cited by 20 - Related Articles - Web Search

Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of ... - all 4 versions »
Y Gaillard, G Pépin - Journal of Chromatography A, 1997 - Elsevier
... 2.697 Adenosine 206.4 3.635 Caffeine **metabolite** 1 206.4 2.74 Imidazole 205.2 3.637 Atenolol 200.5 ... 3.052 Flucytosine 200.5 4.237 Tiapride **metabolite** 212.2 ...
Cited by 26 - Related Articles - Web Search

Recent Advances in the Clinical Pharmacology of Benzodiazepines Part I: Pharmacokinetics
BS MD, GPMDS Psychiatrist - HUMAN PSYCHOPHARMACOLOGY, 1987 - doi.wiley.com
... Parent drug Active **metabolite** Elimination half-live Reference (h) Meanor Range median Midazolam Triazolam Brotizolam **Tofisopam** Cinolazepam ...
Related Articles - Web Search

Absence of Liver DNA Fragmentation in Rats Treated with High Oral Doses of 32 Benzodiazepine Drugs - all 3 versions »
PIA CARLO, F RENATA, A LEDDA, G BRAMBILLA - Toxicological Sciences, 2001 - Soc Toxicology
... diazepam, flunitraz- epam, flurazepam, medazepam, nitrazepam, and **tofisopam**) the dose ... these drugs are extensively trans- formed into **metabolites**, and because ...
Cited by 2 - Related Articles - Web Search

Tofizopam: a benzodiazepine derivative without sedative effect.
J Kanto, L Kangas, T Leppanen, M Mansikka, ML ... - Int J Clin Pharmacol Ther Toxicol, 1982 - ncbi.nlm.nih.gov
... to these results, the active component seems to be an unknown **metabolite** of tofizopam ...
Benzodiazepines; **tofisopam**. PMID: 6125483 [PubMed - indexed for MEDLINE]
Cited by 7 - Related Articles - Web Search

Chromatographic methods
T Cserháti, S Olajos, K Jacob, E Egeler, P Luppa, .. - Analytical and Bioanalytical Chemistry, 1990 - Springer
... prazepam; 15 = clobazam; 16 = **tofisopam**) were dissolved in methanol at a concentration of 1 mg/ml; 500 nl of ... (TDGA) to be the only CMC-**metabolite** detectable in ...
Related Articles - Web Search

Gooogle ▶
Result Page: 1 2 3 **Next**

tofisopam metabolite Search

Google Home - About Google - About Google Scholar